
Bevacizumab JO25567



Bevacizumab JO25567 Bevacizumab JO25567 PRELIMINARY SCORE **CURATIVE CURATIVE NON-CURATIVE NON-CURATIVE** Overall Survival **ADJUSTMENTS** Quality of life No QoL benefit Serious and disabling adverse effects Other adjustments INFORMATION Mature data shows no OS advantage and no improved QoL Control Arm: Erlotinib





© 2024 | European Society for Medical Oncology | ESMO - MCBS 1.1 | All rights reserved worldwide.